Unique ID issued by UMIN | UMIN000038148 |
---|---|
Receipt number | R000042556 |
Scientific Title | The Prospective Observational Study for Realistically Concomitant Use of Corticosteroid in Idiopathic Pulmonary Fibrosis during Treatment with Anti-fibrotic Agents |
Date of disclosure of the study information | 2019/10/01 |
Last modified on | 2020/09/30 21:21:42 |
The Prospective Observational Study for Realistically Concomitant Use of Corticosteroid in Idiopathic Pulmonary Fibrosis during Treatment with Anti-fibrotic Agents
Steroid Treatment for IPF Patients during Anti-fibrotic Agents Therapy
The Prospective Observational Study for Realistically Concomitant Use of Corticosteroid in Idiopathic Pulmonary Fibrosis during Treatment with Anti-fibrotic Agents
Steroid Treatment for IPF Patients during Anti-fibrotic Agents Therapy
Japan |
Idiopathic pulmonary fibrosis
Pneumology |
Others
NO
Researching the safety and efficacy of the combination treatment with both anti-fibrotic agents and corticosteroid for idiopathic pulmonary fibrosis
Safety
Survival rate after 52 weeks
Observational
20 | years-old | <= |
85 | years-old | > |
Male and Female
(1) A Patient who was clinically diagnosed with IPF
(2) Having UIP or probable UIP pattern on HRCT based on the ATS/ERS/JRS/ALAT guideline in 2018
(3) FVC >=50% of predicted, DLCO >=30% of predicted, and FEV1 >=0.7.
(4) Aged >=20 years and <=85 years
(5) All grade of severity (GAP index and Japanese severity of IIPs)
(6) A Patient who will receive nintedanib or pirfenidone or patients who was initiated to treatment with nintedanib or pirfenidone within 1 month
(7) Patients who agree that they participate by written consent
(8) The rate of lymphocyte is more than 30%
(9) One or more the serum auto-immune-related markers, including RF, ANA, anti-DNA, anti-ARS, anti-scl-70, SS-A, SS-B, or ANCA) is positive
(1) Severe heart disease
(2) AST >=1.5*ULN or ALT >=1.5*ULN,
(3) T-bil >=1.5*ULN
(4) Cr >=1.5*ULN
(5) A patient who had ever received anti-cancer agents or radiation therapy
(6) Pregnancy
(7) A patient who can not receive pulmonary function test
(8) A patient who already receive immunosuppressant, including azatiopurinn, cyclosporine, cyclophosphamide, methotrexate, tacrolimus)
(9) Coexistence with pulmonary arterial hypertension, bronchial asthma, Malignant tumor, sarcoidosis, bronchiectasis, respiratory infection
(10) A patient with risk of fatal bleeding
(11) Past history of thrombosis
(12) Having HBV antigen and HVB-DNA
(13) A patient who started clinical trials less than 3 months
(14) A patient improper to this clinical trial according to the decision of a principal investigator
100
1st name | Arata |
Middle name | |
Last name | Azuma |
Nipponn Medical University Musashi Kosugi Hospital
Department of Pulmonary Medicine and Oncology
211-8533
1-396 Kosigi-cho, Nakahara-ku, Kawasaki, Kanagawa
044-733-5181
a-azuma@nms.ac.jp
1st name | Motoyasu |
Middle name | |
Last name | Kato |
Juntendo University Hospital
Department of Respiratory Medicine
113-8431
3-1-3, Hongo, Bunkyo-ku, Tokyo
03-3813-3111
mtkatou@juntendo.ac.jp
Department of Respiratory Medicine, Juntendo University Hospital
Department of Respiratory Medicine, Juntendo University Hospital
Self funding
Juntendo Clinical Research and Trial Center
3-1-3, Hongo, Bunkyo-ku, Tokyo
03-3813-3111
kenkyu5858@juntendo.ac.jp
NO
2019 | Year | 10 | Month | 01 | Day |
Unpublished
Open public recruiting
2019 | Year | 05 | Month | 10 | Day |
2019 | Year | 06 | Month | 20 | Day |
2019 | Year | 06 | Month | 20 | Day |
2023 | Year | 12 | Month | 31 | Day |
Observation study
2019 | Year | 09 | Month | 29 | Day |
2020 | Year | 09 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042556